NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

iclight,

No, not at all. Your lack of understanding the exceptions to adequate and well controlled studies and regulator influence on trial design that was actually beneficial to the patients is your problem not that of the longs, regulators or the patients. Longs are the ones who understand this and that dilution until approval and proof of expected revenue stream that points to profitability by a certain time frame is what keeps the price down with plenty of help from manipulators along the way.
Traders want to see swings in the mean time to make more money while longs keep absorbing the dilution without the help of excited new investors hoping for a quick return on investment. This makes movement of share price relatively easy with small moves one way or the other. When news hits those who were short will go long and work the swings on the way up and back down after being over bought which won’t really happen until institutions get their fill. We are just in the doldrums of retail accumulation and company sales of shares to keep the lights on until news. Unlike what you profess I am looking for the big gap up day that will never be filled because the science and methodology will win the day. It will also likely be utilized as an example in future guidance about how to navigate and overcome some tricky patient welfare considerations during trial setup that might lead to a change in adjudication methods of treatment effect before unblinding. Best wishes.